These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1499617)

  • 1. Erythropoietin in renal cell carcinoma: evaluation of its usefulness as a tumor marker.
    Ljungberg B; Rasmuson T; Grankvist K
    Eur Urol; 1992; 21(2):160-3. PubMed ID: 1499617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum ferritin as a clinical marker for renal cell carcinoma: influence of tumor size and volume.
    Kirkali Z; Güzelsoy M; Mungan MU; Kirkali G; Yörükoglu K
    Urol Int; 1999; 62(1):21-5. PubMed ID: 10436426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive values of acute phase reactants, basic fetoprotein, and immunosuppressive acidic protein for staging and survival in renal cell carcinoma.
    Miyata Y; Koga S; Nishikido M; Noguchi M; Kanda S; Hayashi T; Saito Y; Kanetake H
    Urology; 2001 Aug; 58(2):161-4. PubMed ID: 11489689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiogenesis and other markers for prediction of survival in metastatic renal cell carcinoma.
    Alamdari FI; Rasmuson T; Grankvist K; Ljungberg B
    Scand J Urol Nephrol; 2007; 41(1):5-9. PubMed ID: 17366095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of serum gamma-enolase and aldolase A in combination as markers for renal cell carcinoma.
    Takashi M; Sakata T; Kato K
    Jpn J Cancer Res; 1993 Mar; 84(3):304-9. PubMed ID: 8486529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum immunosuppressive acidic protein as a tumor marker for renal cell carcinoma.
    Igarashi T; Murakami S; Isaka S; Okano T; Shimazaki J; Matsuzaki O
    Eur Urol; 1991; 19(4):332-5. PubMed ID: 1915542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of paraneoplastic erythropoietin production by renal cell carcinomas.
    Gross AJ; Wolff M; Fandrey J; Miersch WD; Dieckmann KP; Jelkmann W
    Clin Investig; 1994 May; 72(5):337-40. PubMed ID: 8086765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of amyloid A immunoexpression in the prognosis of renal cell carcinoma.
    Oz Atalay F; Aytac Vuruskan B; Vuruskan H
    APMIS; 2016 Apr; 124(4):257-62. PubMed ID: 26750935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA.
    Urakami S; Shiina H; Enokida H; Hirata H; Kawamoto K; Kawakami T; Kikuno N; Tanaka Y; Majid S; Nakagawa M; Igawa M; Dahiya R
    Clin Cancer Res; 2006 Dec; 12(23):6989-97. PubMed ID: 17145819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal masses--to treat or not to treat? If that is the question are contemporary biomarkers the answer?
    Uzzo RG
    J Urol; 2008 Aug; 180(2):433-4. PubMed ID: 18550098
    [No Abstract]   [Full Text] [Related]  

  • 11. Critical evaluation of the potential prognostic value of the pretreatment-derived neutrophil-lymphocyte ratio under consideration of C-reactive protein levels in clear cell renal cell carcinoma.
    Dalpiaz O; Luef T; Seles M; Stotz M; Stojakovic T; Pummer K; Zigeuner R; Hutterer GC; Pichler M
    Br J Cancer; 2017 Jan; 116(1):85-90. PubMed ID: 27907929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parathyroid hormone-related protein and serum calcium in patients with renal cell carcinoma.
    Papworth K; Grankvist K; Ljungberg B; Rasmuson T
    Tumour Biol; 2005; 26(4):201-6. PubMed ID: 16006777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C-reactive protein is a predictor of prognosis in renal cell carcinoma patients receiving tyrosine kinase inhibitors: A meta-analysis.
    Wang Z; Peng S; Wang A; Xie H; Guo L; Jiang N; Niu Y
    Clin Chim Acta; 2017 Dec; 475():178-187. PubMed ID: 29080691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble Ligand of the Immune Checkpoint Receptor (sPD-L1) in Blood Serum of Patients with Renal Cell Carcinoma.
    Kushlinskii NE; Gershtein ES; Morozov AA; Goryacheva IO; Filipenko ML; Alferov AA; Bezhanova SD; Bazaev VV; Kazantseva IA
    Bull Exp Biol Med; 2019 Jan; 166(3):353-357. PubMed ID: 30627905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum iron as a tumor marker in renal cell carcinoma.
    Yu CC; Chen KK; Chen MT; Huang JK; Lin AT; Lee YH; Chang LS
    Eur Urol; 1991; 19(1):54-8. PubMed ID: 2007419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased serum cortisol levels are associated with high tumour grade in patients with renal cell carcinoma.
    Rasmuson T; Ljungberg B; Grankvist K; Jacobsen J; Olsson T
    Acta Oncol; 2001; 40(1):83-7. PubMed ID: 11321667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of five glycoprotein tumour markers (CEA, CA-50, CA-19-9, CA-125, CA-15-3) for the prognosis of renal-cell carcinoma.
    Grankvist K; Ljungberg B; Rasmuson T
    Int J Cancer; 1997 Apr; 74(2):233-6. PubMed ID: 9133462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.
    Peña C; Lathia C; Shan M; Escudier B; Bukowski RM
    Clin Cancer Res; 2010 Oct; 16(19):4853-63. PubMed ID: 20651059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher Serum C-reactive Protein Level Represents the Immunosuppressive Tumor Microenvironment in Patients With Clear Cell Renal Cell Carcinoma.
    Nakayama T; Saito K; Kumagai J; Nakajima Y; Kijima T; Yoshida S; Kihara K; Fujii Y
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1151-e1158. PubMed ID: 30213543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated levels of serum aldolase A in patients with renal cell carcinoma.
    Takashi M; Zhu Y; Nakano Y; Miyake K; Kato K
    Urol Res; 1992; 20(4):307-11. PubMed ID: 1509638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.